BuyCancerDrugs.com BuyCancerDrugs.com
BuyCancerDrugs.com BuyCancerDrugs.com
OncologyJournal.org - The Latest Medical News and Information for Patients Diagnosed with Cancer
Search OncologyJournal.org
Browse by Cancer Type or Cancer Drug

Go Back   OncologyJournal.org - The Latest Medical News and Information for Patients Diagnosed with Cancer > Blogs > admin
Connect with Facebook


Cytarabine
Old

Phase 3 Trial of Voreloxin in AML Aft. Completing End-of-Phase 2 Meetings W/ FDA

Posted 02-26-2010 at 04:51 PM by admin
Sunesis Poised for Phase 3 Trial of Voreloxin in Acute Myeloid Leukemia After Completing Formal End-of-Phase 2 Meetings With FDA

Company on Track to Initiate Pivotal Study in Second Half of 2010

CNNMoney.com
Source: Marketwire

February 25, 2010: 07:30 AM ET

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) related to its lead compound,...
Administrator
Comments 0 admin is offline
Old

Combination Therapy W/ Midostaurin Improves Surv. of AML Patients W/FLT3 Mutations

Posted 12-10-2009 at 05:02 PM by admin
Combination Therapy With Midostaurin Improves Survival of Acute Myeloid Leukemia Patients With FLT3 Mutations, Phase 1

ScienceDaily (Dec. 7, 2009) — A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Dec. 7....
Administrator
Comments 0 admin is offline
Old

Sunesis cancer drug gets orphan status, shares soar

Posted 11-24-2009 at 01:17 PM by admin
UPDATE 1-Sunesis cancer drug gets orphan status, shares soar

Thu Nov 5, 2009 9:45am EST

* FDA grants orphan drug status to Voreloxin * Shares up as much as 28 pct

Nov 5 (Reuters) - Biopharmaceutical company Sunesis Pharmaceuticals (SNSS.O) said its experimental cancer drug, voreloxin, got an orphan drug designation from U.S. health regulators, sending its shares soaring 28 percent.

Voreloxin is being developed to treat acute myeloid leukemia (AML),...
Administrator
Comments 0 admin is offline
Old

Cytarabine helps lymphoma remission

Posted 09-22-2009 at 04:45 PM by admin
PharmacyEurope
Monday 21st September 2009

Remission rates for primary central nervous system lymphoma have been boosted by adding cytarabine to high-does methotrexate monochemotherapy, according to research published in the Lancet.

A team at the San Raffaele H Scientific Institute in Milan reports that the combination resulted in remission rates of 46% compared with 18% for methotrexate alone. Partial response rates were 69% and 40%.

Says author Dr Andres...
Administrator
Comments 0 admin is offline
Old

Intense Chemo. Wards Off Recurrence in Half of M.C.Lymphoma Patients After 7 Years

Posted 04-17-2009 at 07:20 PM by admin
Intense Chemotherapy Wards Off Recurrence in Half of Mantle Cell Lymphoma Patients After Seven Years

Tue 09-Dec-2008, 11:40 ET

Newswise — More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

Among patients...
Administrator
Comments 0 admin is offline


All times are GMT. The time now is 05:12 PM.


Powered by vBulletin® Version 3.8.1
Copyright ©2000 - 2010, Jelsoft Enterprises Ltd.